166
Participants
Start Date
May 28, 2020
Primary Completion Date
March 19, 2024
Study Completion Date
March 19, 2025
Obinutuzumab
Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Venetoclax
Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
Fludarabine
Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m\^2), IV, on days 1, 2, and 3 of Cycles 1-6.
Cyclophosphamide
Cyclophosphamide will be administered in a dosage of 250 mg/m\^2, IV, on Days 1, 2, and 3 Cycles 1-6.
Rituximab
Rituximab will be administered at a dose of 375 mg/m\^2, IV, on Cycle 1, Day 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
Bendamustine
Bendamustine will be administered at a dose of 90 mg/m\^2, IV, on 2 consecutive days of Cycles 1-6.
Policlinico Umberto I, Rome
Fondazione Policlinico Universitario Agostino Gemelli, Rome
Royal North Shore Hospital, St Leonards
Liverpool Hospital, Liverpool
Port Macquarie - Mid North Coast Cancer Institute, Port Macquarie
Canberra Hospital, Canberra
Peter MacCallum Cancer Centre;Clinical Haematology, Melbourne
Northern Hospital;Oncology and/or Hematology, Melbourne
Monash Health;Haematology Research, Clayton
AO Santa Maria della Misericordia, Perugia
Royal Hobart Hospital, Hobart
Hospital Universitari Vall d'Hebron;Hematology, Barcelona
Hospital Germans Trias i Pujol, Badalona
Centre Hospitalier Universitaire de Caen Normandie, Caen
Ospedale San Martino;U.O. Clinica Ematologica, Genoa
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico;U.O.C Ematologia, Milan
ASST Grande Ospedale Metropolitano Niguarda;Ematologia, Milan
American Oncology Partners of Maryland, PA, Bethesda
Oncology & Hematology Associates of Southwest Virginia, Inc._Goldschmidt, Roanoke
Hospital Universitario La Paz;Hematología, Madrid
Azienda Ospedaliero Universitaria Maggiore della Carità;SCDU Ematologia, Novara
Hospital General Universitario Morales Meseguer;Hematologia y Oncologia médica, Murcia
COMPLEJO HOSPITALARIO DE NAVARRA;Servicio de Hematología, Pamplona
Hopital Haut Leveque Chu de Bordeaux, Pessac
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau;Hématologie et Thérapie Cellulaire, Tours
University of Tennessee Medical Center;Office of Clinical Trials, Knoxville
Hospital Universitario Virgen del Rocío;Unidad Onco-Hematología Pediátrica, Seville
Azienda Ospedaliero Universitaria;Ematologia, Modena
Hospital Universitario de Toledo, Toledo
Centre Hospitalier Universitaire de Reims - Hôpital Robert Debré;Hématologie Clinique, Reims
Hopital Claude Huriez - CHU de Lille;service maladies appareil digestif, Lille
Centre Hospitalier de Pérpignan;hématologie, Perpignan
centre hospitalier lyon sud;Service Hématologie, Pierre-Bénite
Instituto Tumori Giovanni Paolo II;ONCOLOGIA MEDICA, Bari
Clinique Victor Hugo- CCS du Mans, Le Mans
Ospedale Vito Fazzi;U.O. Ematologia IV Piano Polo Oncologico, Lecce
Medical Center of Aurora, Aurora
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer, Toulon
Centre Hospitalier Universitaire de Poitiers, Poitiers
HENRI MONDOR HOSPITAL;Centre d'investigation clinique, Créteil
Hoffmann-La Roche
INDUSTRY